Dec. 9 at 8:46 AM
$NWBO 🧩 The Three Pillar Convergence:
$NWBO #DCVax,
$INMB INB03, and INKmune in TGF β Dominated Solid Tumors
🔎 TLDR
• The setup: In 2016, Linda Powers (NWBO) and Mark Lowdell (INmune) built Novamune as a shared NK cell IP vehicle, with in vivo NK priming (INKmune) assigned to INmune and ex vivo NK expansion kept in Novamune. Advent BioServices then manufactured both DCVax L and INKmune, and was later acquired by NWBO, giving NWBO control of the shared cell therapy factory and the whole structural stack.
• The problem: TGF β dominated solid tumors are not just hard, they are actively immune excluded. TGF β, MDSCs, adenosine, and dense stroma combine to shut down NK cells, block IL 12 from dendritic cells, exhaust T cells, and keep most checkpoint inhibitors from ever seeing an active signal. Failure here is not bad luck, it is baked into the biology.
• Pillar one, DCVax L (adaptive engine): DCVax L uses whole tumor lysate loaded into type 1 polarized dendritic cells that are matured ex vivo to produce high IL 12, IL 15, and IL 18. That creates broad, durable, tumor specific T cell and tissue resident memory responses in a setting that TGF β cannot suppress.
• Pillar two, INB03 (myeloid reset): INB03 selectively neutralizes soluble TNF, shrinking and reprogramming MDSCs, lowering CD39 and CD73 and adenosine, and shifting macrophages toward M1. The result is a TME that regains chemokines, loses much of its suppressive myeloid fog, and becomes accessible to T cells and NK cells.
• Pillar three, INKmune (innate offensive line): INKmune is a replication incompetent tumor line that directly engages resting NK cells through multiple receptors at once, converting them into long lived, memory like NK cells with strong interferon gamma output. These NK cells kill antigen loss and MHC low variants, feed new antigens back to dendritic cells, and help maintain an inflammatory chemokine and cytokine loop.
• The convergence: When DCVax L seeds adaptive immunity, INB03 clears the myeloid and adenosine barricade, and INKmune turns NK cells into a persistent search and destroy force, the three systems lock together into a sustained loop. T cells handle known targets, NK cells sweep escape variants, and the remodeled TME can no longer easily revert to immune exclusion.
• Why it matters: Through Novamune, Advent, and Lowdell, NWBO and INmune already have the IP, the shared manufacturing track record, and the regulatory experience to run this combination. If DCVax L approval and INB03 or INKmune Phase 2 data arrive as expected, a three pillar trial in TGF β heavy solid tumors becomes not only plausible but strategically difficult to ignore.
🧷 Context Note
This narrative is based on due diligence originally compiled by @FlemmingBruce , whose work mapped key connections among NWBO, Advent BioServices, Novamune, INmune Bio, and Professor Mark Lowdell.
Link: http://investorshub.advfn.com/boards/read_ms…
👉 https://x.com/andrewcaravello/status/1998219521757192691?s=46
